Carlos Eduardo Lazarini da Fonseca

Crescimento inicial de Piptadenia gonoacantha (Leguminosae, Mimosoideae) sob inundação em diferentes níveis de luminosidade

This study focus on ecological aspects of flooding on five month old seedlings of Piptadenia gonoacantha, a Gallery forest species. Seedling growth rates were evaluated on three levels of sun light (100%, 70% and 40%) and two soil moisture conditions (field capacity and flooded). Flooding reduced aerial and root growth. There was no interaction between light intensity and flooding, except for foliar dry matter (60 days) and top/root ratio (20 days). Full sun light seedlings under flooding had 67% lower foliar dry matter production than shaded ones, after 60 days. Flooded seedlings in all three light levels, had hypertrophic lenticels on submerged stems, after 20 days. In additon, flooding induced root decomposition but no adventicious roots were observed. After 60 days of flooding, seedlings of P. gonoacantha presented 100 % survival and no significant injury on the top portion.

Effect of Meloidogyne javanica on the growth of pea

The root-knot nematode, Meloidogyne javanica commonly causes yield reduction of pea (Pisum sativum L.) in the Federal District of Brazil. The effect of M. javanica on the growth of pea cv. Triofin was studied with five inoculum levels namely 0, 10, 100, 1,000, and 10,000 eggs/kg of soil under greenhouse conditions. There was a progressive decrease in plant growth as the inoculum levels of nematode increased. The rate of nematode multiplication was inversely proportional to the inoculum level. Rhizobial nodulation was adversely affected at all the inoculum levels except for the inoculum level of 10 eggs/kg of soil which showed a 61.63% increase in number of bacterial nodules.

Repetibilidade de características de frutos de duas populações de Hancornia speciosa da região “core” do Cerrado do Brasil

The objective of this work was to estimate the repeatability coefficients of mangaba (Hancornia speciosa) fruit traits, in order to define the number of fruit needed for an accurate selection of superior genotypes, as well as to conjecture about the nature of the phenotypic variation of these traits. Evaluations were performed for 160 fruit of 16 genotypes from two native H. speciosa populations of Goiás Velho and Padre Bernardo, in the state of Goiás, Brazil. Repeatability was estimated by the analysis of variance, principal component analyses based on covariance and on the correlation matrix, and structural analysis based on the correlation matrix. Repeatability estimates for fruit weight, diameter, and length, as well as seed number and weight, were of low magnitude, from 0.02 to 0.62, indicating low heritability. Repeatability estimates for oBrix, titratable acidity, and oBrix/acidity ratio were higher, from 0.34 to 0.91, indicating a low to potentially moderate heritability. The number of fruit for an effective selection of the best genotypes for titratable acidity, oBrix, oBrix/acidity ratio, and fruit weight is four for a 0.85 accuracy level. However, seven fruit would allow 0.90 accuracy for the same traits, and 0.85 accuracy for fruit length and diameter. The number and weight of seed per fruit are not effective for predicting the real value of a genotype.

FRI0139 Serologic Profile and Reactivation of Hepatitis B in Rheumatic and Inflammatory Bowel Disease Patients Treated with Biologic Therapies

Background Biologic therapy for rheumatic diseases (RD) and inflammatory bowel disease (IBD) has been associated with increased risk of reactivation of latent infections such as hepatitis B (HB). However, the actual risk of HB reactivation is still unclear, especially in low-endemic countries such as Portugal. Objectives To evaluate the serologic HB profile of rheumatic and IBD patients exposed to biologics in two centres. To characterize and assess the incidence of HB reactivation in patients with evidence of past HB infection. Methods We collected available HB serology of rheumatic patients that ever started biological therapy at our departments. We reviewed the clinical course to identify reactivation cases, defined as raising transaminases, de novo detection of AgHBs and/or positive viral load. Anti-HBc positive patients were studied as to clinical and treatment characteristics. Results We identified 934 patients with available data on HB serologies (710 RD, 224 IBD) that corresponded to a cumulative biologics exposure of 3904.4 patient-years. All of the patients were AgHBs negative, 72 (8.5%) were anti-HBc positive and viral load was undetectable in every case (Figure 1). In the anti-HBc positive subpopulation, two thirds were females, median age at biologic start was 54.1 years (interquartile range [IQR] 41.3-60.6) and median disease duration was 6.6 years (IQR 3.3-11.1). Sixty-one had a RD diagnosis (9.8% of total; 31 rheumatoid arthritis [10.9%], 12 ankylosing spondylitis [6.9%], 10 psoriatic arthritis [11.2]) and 11 had IBD (5.0% of total; 10 Crohns disease [5.7%], 1 ulcerative colitis [2.5]). Amongst anti-HBc positive patients, the most frequent initial biologic was infliximab (38.9%), followed by etanercept (31.9%), adalimumab (12.5%), golimumab (5.6%), tocilizumab (5.6%) and rituximab (5.6%). Only 5.6% eventually stopped biologic treatment during follow-up. Forty-four patients (61%) were concomitantly treated with methotrexate (69% of RD and 18% of IBD patients), 43 (60%) with other DMARDs (56% of RD and 82% of IBD patients) and 51 (71%) were on corticosteroids (71% of RD, 73% of IBD patients). No patient received prophylactic antiviral therapy and there was only one case of HB reactivation, a Crohns disease patient with prior history of acute HB, anti-HBc/anti-HBs positive and initially treated with adalimumab plus azathioprine. She was switched to infliximab because of poor response and at the time she had lost anti-HBs positivity while maintaining anti-HBc. Severe HB reactivation ensued after 13 months of treatment, infliximab was stopped and anti-viral therapy started with a favorable outcome. Conclusions In our cohort of 934 rheumatic and IBD patients, anti-HBc positivity was infrequent, viral load undetectable and there were no chronic HB cases. There was one case of HB reactivation in a anti-HBc+/anti-HBs- patient treated with infliximab. In a low incidence setting, HB reactivation following biologic therapy is likely to be a much rarer event than what has been previously reported. Disclosure of Interest None declared